Indications -- Cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (741)	4/19/2005 3:11:32 PM
From: Ian@SI	Read Replies (1) of 1840

Listened to PFE's earnings conf call today (or most of it at least). News to me came in the Q&A re SU-11248 (Suten). Apparently it will be presented a few times at ASCO for more than just the renal cancer trial that made recent headlines. Hank M. also advised that oncologists have expressed substantial enthusiasm re Suten, something which he regards as a rather positive early warning signal. As I've never seen/heard him hype any of his products, this optimism convinced me to get back in this PM. Too bad that it was still trading higher than my exit price prior to the MRK IP trial win. :-( Oh well, if the market gives PFE a similar Mkt Cap boost for Suten as DNA got for Avastin, we could see as much as $3-$4 a share. ;-) Best, Ian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next